- Ticker
- ACHV
- Price
- 5.20
- Stock movement up
- +0.21 (4.21%)
- Company name
- Achieve Life Sciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 93.06M
- Ent value
- 97.55M
- Price/Sales
- -
- Price/Book
- 89.14
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -30.11%
- 3 year return
- -24.29%
- 5 year return
- -55.62%
- 10 year return
- -57.94%
Last updated: 2023-02-03
DIVIDENDS
ACHV does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 89.14 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 17.90M |
| EPS (TTM) | -3.95 |
| FCF per share (TTM) | -3.26 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -37.05M |
| Net income (TTM) | -38.27M |
| EPS (TTM) | -3.95 |
| EPS (1y forward) | -2.27 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 18.20M |
| Net receivables | 145.00K |
| Total current assets | 20.96M |
| Goodwill | 1.03M |
| Intangible assets | 1.48M |
| Property, plant and equipment | 0.00 |
| Total assets | 23.72M |
| Accounts payable | 6.89M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 6.92M |
| Total liabilities | 22.68M |
| Shareholder's equity | 1.04M |
| Net tangible assets | -1.47M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -31.62M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -31.62M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -3665.61% |
| Return on Assets | -161.32% |
| Return on Invested Capital | -227.70% |
| Cash Return on Invested Capital | -188.16% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.95 |
| Daily high | 5.25 |
| Daily low | 4.95 |
| Daily Volume | 74K |
| All-time high | 1821600.00 |
| 1y analyst estimate | 24.75 |
| Beta | 1.18 |
| EPS (TTM) | -3.95 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 8 Mar 2023 |
Downside potential
Loading...
Downside potential data
| ACHV | S&P500 | |
| Current price drop from All-time high | -100.00% | -13.68% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 6 Jan 2023 | 9 Mar 2009 |
| Avg drop from high | -88.20% | -11.49% |
| Avg time to new high | 93 days | 13 days |
| Max time to new high | 6370 days | 1805 days |
COMPANY DETAILS
Marketcap
93.06M
Marketcap category
Small-cap
Description
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Employees
16
Investor relations
-
SEC filings
CEO
Richard Alistair Balfour Stewart
Country
USA
City
Vancouver
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global develo...
February 2, 2023
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
January 27, 2023
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global develo...
January 9, 2023
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Call Transcript November 14, 2022 Achieve Life Sciences, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, expectations were ...
December 29, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development...
December 21, 2022
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter 2022 results in a press release and held a conference call aft...
November 21, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global develo...
November 15, 2022
Company to host conference call at 4:30 PM EST today, November 14, 2022SEATTLE and VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-sta...
November 14, 2022
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
Phase 2 ORCA-V1 Data Expected in 1H2023SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical...
November 8, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global develo...
October 31, 2022
Next page